After discontinuation of haloperidol and quetiapine in a patient with TdP, what is the most appropriate treatment?

In the context of treating a patient with Torsades de Pointes (TdP), the selection of initiating an isoproterenol infusion is appropriate due to its mechanism of action on the heart. Isoproterenol, a non-selective beta-adrenergic agonist, increases the heart rate and can help correct the lengthened QT interval that contributes to TdP. By enhancing the heart's automaticity and suppressing the abnormal electrical activity that can lead to TdP, isoproterenol effectively serves as a treatment strategy in these situations.

Torsades de Pointes is often associated with prolonged QT intervals, which can result from various factors, including the use of certain medications like haloperidol and quetiapine. When these medications are discontinued due to their contribution to the development of TdP, managing the underlying cause—with a strategy like isoproterenol infusion—becomes critical.

In addition to isoproterenol, magnesium may also be administered to stabilize the cardiac arrhythmia; however, the most effective acute intervention to combat the arrhythmia and increase heart rate and automaticity is the administration of isoproterenol. Thus, in choosing isoproterenol as the treatment modality, you employ a direct